GM viruses can treat brain tumors; Drug-eluting stent market to hit $6B by 2015;

> Genetically modified viruses engineered to destroy cancer cells might be more effective in treating deadly brain tumors if equipped with an enzyme that helps them penetrate the tumor. Report

> The global market for drug-eluting stents is expected to reach $6 billion by 2015, according to a new report. Report

> Arrowhead Research Corp., based in Pasadena, Calif., has increased its investment in RNAi drug delivery company Calando Pharmaceuticals. According to a news release, Arrowhead has invested $1 million in Calando and converted approximately $8 million of Calando debt to Arrowhead into equity. Release

> TransPharma Medical has changed the name of its drug delivery system ViaDerm to ViaDor, which is a handheld electronic device that creates microscopic passageways through the outer layer of the skin allowing for transdermal delivery of a wide variety of drugs from a patch. News

> Drug delivery abstract of the week: Ultrasound-Mediated Transdermal Drug Delivery: Mechanisms, Scope, and Emerging Trends. Abstract

> Drug delivery patent application of the week: Compositions and methods for controlled delivery of inhibitory ribonucleic acids Patent application

Suggested Articles

The new digital Abilify is a breakthrough for Proteus Digital Health and its patient-tracking products, but not so much for Abilify's maker, Otsuka.

Adamis Pharmaceuticals' EpiPen contender Symjepi, which was rejected last year before the EpiPen havoc, won approval from the FDA.

Researchers in the U.K. have developed a technique to better predict results in liver cancer when drug-laden polymer beads are used to deliver medicines.